D.E. Shaw & Co
CYTK icon

D.E. Shaw & Co’s Cytokinetics CYTK Stock Holding History

D.E. Shaw & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,700
Closed -$2.68M – 4932
2026
Q1 		$2.68M Sell
40,700
-40,800
-50% -$2.59M ﹤0.01% 2692
2025
Q4 		$5.18M Buy
81,500
+8,800
+12% +$547K ﹤0.01% 2268
2025
Q3 		$4M Sell
72,700
-8,900
-11% -$367K ﹤0.01% 2416
2025
Q2 		$2.7M Buy
81,600
+8,900
+12% +$310K ﹤0.01% 2516
2025
Q1 		$2.92M Sell
72,700
-11,600
-14% -$533K ﹤0.01% 2322
2024
Q4 		$3.97M Sell
84,300
-35,000
-29% -$1.82M ﹤0.01% 2165
2024
Q3 		$6.3M Hold
119,300
– – 0.01% 1775
2024
Q2 		$6.46M Buy
119,300
+55,000
+86% +$3.32M 0.01% 1654
2024
Q1 		$4.51M Buy
+64,300
New +$4.97M ﹤0.01% 1973

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's CYTK Position: Q2 2026 in Review

D.E. Shaw & Co increased its Cytokinetics (CYTK) stake by 48% in Q2 2026, buying an estimated $24.5M and bringing the position to 1,048,103 shares worth $89.3M. The position accounts for 0.04% of the portfolio, ranked #490.

D.E. Shaw & Co first reported a position in CYTK in Q3 2013 and has held it in 39 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • D.E. Shaw & Co held 1,048,103 shares of Cytokinetics worth $89.3M as of Q2 2026.
  • D.E. Shaw & Co bought 341,472 Cytokinetics shares in Q2 2026, an estimated $24.5M.
  • Cytokinetics made up 0.04% of D.E. Shaw & Co's portfolio in Q2 2026, its #490 holding.
  • D.E. Shaw & Co first reported a position in Cytokinetics in Q3 2013 and has held it in 39 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.